Cardiovascular Diabetology, 2020 Background Studies assessing the efficacy of pioglitazone solely for primary stroke prevention in Asian patients with type 2 diabetes mellitus (DM) and present multiple cardiovascular (CV) risk factors are rare.
Yi-Chih Hung +3 more
doaj +1 more source
RPB4 and pathogenesis of diabetes [PDF]
, 2007 Obesity is an important risk factor for a number of chronic diseases that impose a huge burden on individuals and society. Recently it has become clear that adipose tissue-secreted products may play a significant role in mediating many obesity-related ...
Kumar, Sudhesh +1 more
core +1 more source
Frontiers in Pharmacology, 2017 Pioglitazone is a type of peroxisome proliferator-activated receptor γ (PPARγ) agonist and has been demonstrated to be effective in chronic kidney diseases (CKD) treatment.
Li Sun +8 more
doaj +1 more source
Short-term therapy with rosiglitatzone, a PPAR-¿ agonist improves metabolic profile and vascular function in non-obese lean wistar rats [PDF]
, 2012 A number of preclinical and clinical studies have reported blood-pressure-lowering benefits of thiazolidinediones in diabetic subjects and animal models of diabetes.
Abubakari, Abdul-Razak +3 more
core +1 more source
Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]
, 2014 The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen +58 more
core +10 more sources
Probiotics ameliorate pioglitazone-associated bone loss in diabetic rats
Diabetology & Metabolic Syndrome, 2020 Background Pioglitazone, as a PPAR gamma agonist, is used for the management of type 2 diabetes mellitus. Nevertheless, evidence showed that the therapeutic modulation of PPAR gamma activity using pioglitazone might be linked with bone mass reduction and
Ahmad Gholami +5 more
doaj +1 more source
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. [PDF]
PLoS ONE, 2014 Fetuin-A, a circulating glycoprotein synthesized in the liver, is involved in insulin resistance and type 2 diabetes. However, regulation of fetuin-A synthesis has remained obscure. We previously reported that pioglitazone treatment significantly reduced
Akinobu Ochi +10 more
doaj +1 more source
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [PDF]
, 2016 Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of
Avogaro, Angelo +4 more
core +3 more sources
Journal of Pharmacological Sciences, 2019 Visceral hypersensitivity and impaired gut barrier with minor inflammation are considered to play an important role in the pathophysiology of irritable bowel syndrome (IBS).
Tsukasa Nozu +4 more
doaj +1 more source
Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms [PDF]
, 2018 Hypertension and type 2 diabetes are common comorbidities. Hypertension is twice as frequent in patients with diabetes compared with those who do not have diabetes.
Guzik, Tomasz J. +2 more
core +1 more source